Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis

Translational Oncology

Volumn 5, Issue 5, 2012, Pages 344-355

  Wang, Lei ^a   Ho, Jeffrey ^a   Glackin, Carlotta ^b   Martins Green, Manuela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEIC ACID; ELLAGIC ACID; LUTEOLIN; MICRORNA; PUNICIC ACID; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; CANCER CELL; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL CYCLE REGULATION; CHEMOTAXIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; POMEGRANATE JUICE; PROSTATE CANCER;

EID: 84867567728     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12190     Document Type: Article

References (49)

1. Stavridi F, Karapanagiotou EM, and Syrigos KN (2010). Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 36, 122-130.
2. Coffey DS and Pienta KJ (1987). New concepts in studying the control of normal and cancer growth of the prostate. Prog Clin Biol Res, 1-73.
3. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, and Su LC (2011). Androgens as therapy for androgen receptor-positive castrationresistant prostate cancer. J Biomed Sci 18, 63.
4. Petrylak DP (1999). Chemotherapy for advanced hormone refractory prostate cancer. Urology 54, 30-35.
5. Harzstark AL and Small EJ (2010). Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin Pharmacother 11, 937-945.
6. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, and Kantoff PW (2010). Sipuleucel-T. Nat Rev Drug Discov 9, 513-514.
7. Shah S and Ryan CJ (2009). Abiraterone acetate CYP17 inhibitor oncolytic. Drugs Fut 34, 873-880.
8. Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446.
9. Schrijvers D, Van Erps P, and Cortvriend J (2010). Castration-refractory prostate cancer: new drugs in the pipeline. Adv Ther 27, 285-296.
10. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al. (2011). Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10, 2298-2308.
11. Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, Gordon MS, Vogelzang NJ, Scheffold C, Ballinger MD, and Hussain M (2011). Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J Clin Oncol 29(suppl 7), Abstract 127.
12. Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, GommersallLM, Patel A, Mansel RE, Neeman I, Geldof AA, and Campbell MJ (2004). Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7, 274-283.
13. Syed DN, Suh Y, Afaq F, and Mukhtar H (2008). Dietary agents for chemoprevention of prostate cancer. Cancer Lett 265, 167-176.
14. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, et al. (2008). Pomegranate extract inhibits androgenindependent prostate cancer growth through a nuclear factor-κβ-dependent mechanism. Mol Cancer Ther 7, 2662-2671.
15. Pantuck AJ, Leppert JT, Zomorodian N, Seeram N, Seiler D, Liker H, Wang H-J, Elashoff R, Heber D, and Belldegrun AS (2005). Phase II study of pomegranate juice for men with rising PSA following surgery or radiation for prostate cancer. J Urol 173, 225-226.
16. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, and Mukhtar H (2005). Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102, 14813-14818.
17. Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, Harris NM, Neeman I, and Campbell MJ (2005). Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 23, 11-20.
18. Wang L, Alcon A, Yuan H, Ho J, Li QJ, and Martins-Green M (2011). Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 3, 742-754.
19. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, et al. (2002). Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71, 203-217.
20. Syed DN, Afaq F, and Mukhtar H (2007). Pomegranate derived products for cancer chemoprevention. Semin Cancer Biol 17, 377-385.
21. Adhami VM, Khan N, and Mukhtar H (2009). Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer 61, 811-815.
22. Gil MI, Tomas-Barberan FA, Hess-Pierce B, HolcroftDM, and Kader AA (2000). Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 48, 4581-4589.
23. El Kar C, Ferchichi A, Attia F, and Bouajila J (2011). Pomegranate (Punica granatum) juices: chemical composition, micronutrient cations, and antioxidant capacity. J Food Sci, C795-C800.
24. Zhou Q, Yan B, Hu X, Li XB, Zhang J, and Fang J (2009). Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther 8, 1684-1691.
25. Grossmann ME, Mizuno NK, Schuster T, and Cleary MP (2010). Punicic acid is an ω-5 fatty acid capable of inhibiting breast cancer proliferation. Int J Oncol 36, 421-426.
26. Gasmi J and Sanderson JT (2010). Growth inhibitory, antiandrogenic, and proapoptotic effects of punicic acid in LNCaP human prostate cancer cells. J Agric Food Chem 58, 12149-12156.
27. Lansky EP, Harrison G, Froom P, and Jiang WG (2005). Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs 23, 379.
28. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, and Vessella RL (2003). Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20, 171-180.
29. Lin S-L, Chang D, and Ying S-Y (2007). Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis 28, 310-320.
30. Glotzer M (2005). The molecular requirements for cytokinesis. Science 307, 1735-1739.
31. Ohtsuka T, Nakanishi H, Ikeda W, Satoh A, Momose Y, Nishioka H, and Takai Y (1998). Nexilin: a novel actin filament-binding protein localized at cellmatrix adherens junction. J Cell Biol 143, 1227-1238.
32. Thiery JP, Acloque H, Huang RY, and Nieto MA(2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
33. Kang Y and Massague J (2004). Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118, 277-279.
34. Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
35. Higa LA, Banks D, Wu M, Kobayashi R, Sun H, and Zhang H (2006). L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle 5, 1675-1680.
36. Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP, and Houchen CW (2011). Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology 9, 40.
37. Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, OzataDM, Xie H, Lindforss U, Olivecrona H, and Lui WO (2011). miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 39, 311-318.
38. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, and Matsubara H (2010). miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127, 2804-2814.
39. Leone V, D'Angelo D, Rubio I, de Freitas PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G, and Fusco A (2011). MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1α. J Clin Endocrinol Metab 96, E1388-E1398.
40. Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Sasaki K, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nakagawa M, et al. (2011). Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol 39, 1099-1107.
41. Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C, Iaboni M, Nuovo G, Croce CM, and Condorelli G (2010). miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 70, 3638-3646.
42. Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D, Lilja H, and Ceder Y (2010). miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127, 2768-2776.
43. Cai KM, Bao XL, Kong XH, Jinag W, Mao MR, Chu JS, Huang YJ, and Zhao XJ (2010). Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. Int J Mol Med 25, 565-571.
44. Korpal M, Lee ES, Hu G, and Kang Y (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283, 14910-14914.
45. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, and Massague J (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152.
46. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al. (2011). The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut, 278-289.
47. Zhu S, Wu H, Wu F, Nie D, Sheng S, and Mo YY (2008). MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18, 350-359.
48. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al. (2010). miR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12, 247-256.
49. Wang C, Bian Z, Wei D, and Zhang JG (2011). miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 352, 197-207.